MedTrace Logo

Study of Surufatinib Combined With Sintilimab and SCRT in Advanced Solid Tumors

NCT05527821 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2022-09-06

No results posted yet for this study

Summary

An exploratory clinical study of short course radiotherapy combined with surufatinib and sintilimab in the treatment of relapsed and refractory advanced solid tumors

Conditions

  • Unresectable Advanced Solid Tumors
  • Biliary Tract Tumors, Gastric Cancer, Small Cell Lung Cancer

Interventions

DRUG

Surufatinib

Surufatinib 250mg will be taken orally once daily continuously on a 21-day cycle

DRUG

Sintilimab

Sintilimab 200mg will be intravenously administered on Day 1 of each cycle

RADIATION

Short course radiotherapy

5Gy\*5F short course radiotherapy will be delivered

Sponsors & Collaborators

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-30
Primary Completion
2024-09-30
Completion
2025-09-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05527821 on ClinicalTrials.gov